Osiris halts enrolment in Phase III Prochymal trial in Crohn's
This article was originally published in Scrip
Executive Summary
Osiris Therapeutics has terminated enrolment in its Phase III study evaluating its stem cell therapy, Prochymal, for Crohn's disease, citing a major trial design flaw as the reason